<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11677">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02011906</url>
  </required_header>
  <id_info>
    <org_study_id>95983</org_study_id>
    <nct_id>NCT02011906</nct_id>
  </id_info>
  <brief_title>The Effects of Omega 3 and Vitamin E Supplementation on the Serum Antioxidant Enzymes and Gene Expressions of PGC-1a, h TERT, FOXOs and SIRTs in CAD Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <authority>Iran: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine the effects of omega 3 supplementation and  its
      concurrent supplementation with vitamin E  on the serum levels of antioxidant enzymes and
      the expressions of the PGC-1a, h TERT, FOXO1, FOXO3a , SIRT1,SIRT3, SIRT6 genes in PBMC
      cells in the patients with coronary artery disease
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>serum total cholesterol</measure>
    <time_frame>change from baseline at 2 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>serum HDL cholesterol</measure>
    <time_frame>change from baseline at 2 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>serum triglycerides level</measure>
    <time_frame>change from baseline at 2 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>serum LDL cholesterol</measure>
    <time_frame>change from baseline at 2 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>serum insulin</measure>
    <time_frame>change from baseline at 2 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>serum Hs-CRP</measure>
    <time_frame>change from baseline at 2 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>serum gluthatione peroxidase</measure>
    <time_frame>change from baseline at 2 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>serum catalase</measure>
    <time_frame>change from baseline at 2 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>serum superoxide dismutase</measure>
    <time_frame>change from baseline at 2 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>serum total antioxidant capacity</measure>
    <time_frame>change from baseline at 2 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>gene expression of SIRT1</measure>
    <time_frame>change from baseline at 2 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gene expression of SIRT3</measure>
    <time_frame>change from baseline at 2 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gene expression of SIRT6</measure>
    <time_frame>change from baseline at 2 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gene expression of PGC-1a</measure>
    <time_frame>change from baseline at 2 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gene expression of FOXO3a</measure>
    <time_frame>change from baseline at 2 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gene expression of FOXO1</measure>
    <time_frame>change from baseline at 2 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gene expression of h TERT</measure>
    <time_frame>change from baseline at 2 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>CAD, OMEGA 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients with CAD who receive 4 gr/day omega 3 in the form of 4 softgels each of them contains 1000 mg omega 3 and a softgel contains placebo of vitamin E</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CAD, omega 3 and vitamin E</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients with CAD who receive 4 gr/day omega 3 in the form of 4 softgels each of them contains 1000 mg omega 3 and a softgel contains 400 IU vitamin E</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CAD, placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients with CAD who receive 4 softgels/day each of them contains placebo of omega 3 and a softgel/day contains placebo of vitamin E</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>omega 3</intervention_name>
    <arm_group_label>CAD, OMEGA 3</arm_group_label>
    <arm_group_label>CAD, omega 3 and vitamin E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>vitamin E</intervention_name>
    <arm_group_label>CAD, omega 3 and vitamin E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo of omega 3</intervention_name>
    <arm_group_label>CAD, placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo of vitamin E</intervention_name>
    <arm_group_label>CAD, OMEGA 3</arm_group_label>
    <arm_group_label>CAD, placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -

        literate, willingness to participation, CAD patients 45- 65 years old, body mass index&lt;
        30, avoidance of dietary supplements, vitamins and herbal products at least 3 months
        before and throughout the intervention, willing to maintain body weight during the study

        Exclusion Criteria:

          -  people who have used vitamin E or omega 3 supplements in last 3 months, having
             chronic renal disease ,cancer, Hepatobilliary diseases, hematological disorders,
             hypo- or hyperthyroidism, diabetes, treatment with PPAR-gamma agonists or
             Thiazolidinediones, Smokers
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tehran University of Medical Sciences</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 10, 2013</lastchanged_date>
  <firstreceived_date>December 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>antioxidant enzymes</keyword>
  <keyword>omega 3</keyword>
  <keyword>vitamin E</keyword>
  <keyword>CAD</keyword>
  <keyword>Sirtuins</keyword>
  <keyword>FOXOs</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antioxidants</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Alpha-Tocopherol</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
